Chapitre V Rfrences bibliographiques Correspondances en MHDN Rfrences

Chapitre V Références bibliographiques Correspondances en MHDN

Références bibliographiques (1) • American Diabetes Association. Standards of medical care in diabetes-2007. Diabetes Care 2007; 30(suppl 1): S 4 -41 • Das SR et al. 2018 ACC Expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol 2018; 72(24): 3200 -23 • Cosentino F et al. Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable. Eur Heart J 2018. doi: 10. 1093/eurheartj/ehy 677 [Epub ahead of print] • Packer M. How should we judge the efficacy of drug therapy in patients with chronic congestive heart failure? The insights of six blindmen. J Am Coll Cardiol 1987; 9(2): 433 -8 • UKPDS. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352(9131): 837 -53 • Action to Control Cardiovascular Risk in Diabetes Study Group et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358(24): 2545 -59 • NICE-SUGAR Study Investigators et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009; 360(13): 1283 -97 • Boussageon R et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 2011; 343: d 4169 • Nissen SE et al. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 2005; 294(20): 2581 -6 • Nissen SE et al. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356(24): 2457 -71 • Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: diabetes mellitus-evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. 2008 • Rydén L et al. Clinical implications of cardiovascular outcome trials in type 2 diabetes: from DCCT to EMPA-REG. Clin Ther 2016; 38(6): 1279 -87 • White WB et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369(14): 1327 -35 • Green JB et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015; 373(3): 232 -42 • Marso SP et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375(4): 311 -22 • Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016; 375(19): 1834 -44 Correspondances en MHDN 1

Références bibliographiques (2) • Zinman B et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373(22): 2117 -28 • Scirica BM et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369(14): 1317 -26 • Neal B et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377(7): 644 -57 • Hernandez AF et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 2018; 392(10157): 1519 -29 • Holman RR et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2017; 377(13): 1228 -39 • Pfeffer MA et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015; 373(23): 2247 -57 • Wiviott SD et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019; 380(4): 347 -57 • Rosenstock J et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA 2019; 321(1): 69 -79 • Vergès B et al. Liraglutide reduces postprandial hyperlipidemia by increasing apo. B 48 (apolipoprotein B 48) catabolism and by reducing apo. B 48 production in patients with type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 2018; 38: 2198 -2206 • Lehmann R et al. Recommandation SSED/SGED : mesures visant le contrôle de la glycémie chez les patients atteints de diabète sucré de type 2. Berne, SSED-SGED 2016 • Darmon P et al. Prise de position de la Société Francophone du Diabète (SFD) sur la prise en charge médicamenteuse de l’hyperglycémie du patient diabétique de type 2. Médecine des Maladies Métaboliques 2017; 11(6): 577 -93 • Davies MJ et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2018; 61(12): 2461 -98 Correspondances en MHDN 2

Déclaration publique de liens d’intérêts • François Diévart déclare avoir des liens d’intérêts avec Alliance BMS-Pfizer, AMGEN, Astra. Zeneca, Bayer, BMS, Pfizer, Boerhinger Ingelheim, MSD, Novartis, Novo Nordisk, Takeda, Sanofi-Aventis France, Servier Correspondances en MHDN 3